TreeFrog Therapeutics is a leading biotech company based in France, with a vision to provide safe, efficient, and affordable cell therapies for millions of patients. Founded in 2018, TreeFrog Therapeutics has experienced hyper-growth and has been expanding in France, the USA, and Japan. The company brings together a team of biophysicists, stem cell biologists, and bioproduction engineers to develop innovative cell therapies, including their flagship product C-Stem™.

The company's executive team is comprised of industry experts with extensive experience in biotechnology, finance, strategic consulting, and pharmaceuticals. They are all driven by a common mission to bring innovative, more affordable cell therapies to millions through proprietary therapeutic programs and external partnerships. With a focus on research and development, TreeFrog Therapeutics is dedicated to providing cutting-edge solutions based on their biomimetic C-Stem™ technology, which allows for the mass production of induced pluripotent stem cells and their differentiation into ready-to-transplant microtissues, all while maintaining scalability and cell quality.

Through their innovative approach and strategic partnerships, TreeFrog Therapeutics is revolutionizing the field of cell therapies and making a significant impact on the lives of patients worldwide